Bifogade filer
Kurs
+8,05%
Kalender
Est. tid* | ||
2026-06-04 | 07:00 | Bokslutskommuniké 2026 |
2026-03-02 | 07:00 | Kvartalsrapport 2026-Q3 |
2025-12-01 | 07:00 | Kvartalsrapport 2026-Q2 |
2025-09-25 | N/A | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2025-09-24 | N/A | Årsstämma |
2025-09-01 | 07:00 | Kvartalsrapport 2026-Q1 |
2025-06-03 | - | Bokslutskommuniké 2025 |
2025-03-03 | - | Kvartalsrapport 2025-Q3 |
2025-01-20 | - | Extra Bolagsstämma 2025 |
2024-12-04 | - | Kvartalsrapport 2025-Q2 |
2024-09-26 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2024-09-25 | - | Årsstämma |
2024-08-29 | - | Kvartalsrapport 2025-Q1 |
2024-05-30 | - | Bokslutskommuniké 2024 |
2024-02-29 | - | Kvartalsrapport 2024-Q3 |
2023-12-04 | - | Kvartalsrapport 2024-Q2 |
2023-10-04 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2023-09-27 | - | Årsstämma |
2023-08-31 | - | Kvartalsrapport 2024-Q1 |
2023-06-08 | - | Bokslutskommuniké 2023 |
2023-03-01 | - | Kvartalsrapport 2023-Q3 |
2022-12-01 | - | Kvartalsrapport 2023-Q2 |
2022-10-03 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2022-09-28 | - | Årsstämma |
2022-08-31 | - | Kvartalsrapport 2023-Q1 |
2022-06-10 | - | Bokslutskommuniké 2022 |
2022-03-02 | - | Kvartalsrapport 2022-Q3 |
2021-12-02 | - | Kvartalsrapport 2022-Q2 |
2021-09-09 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2021-09-02 | - | Kvartalsrapport 2022-Q1 |
2021-05-31 | - | Bokslutskommuniké 2021 |
2021-03-03 | - | Kvartalsrapport 2021-Q3 |
2020-12-02 | - | Kvartalsrapport 2021-Q2 |
2020-09-30 | - | Årsstämma |
2020-09-09 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2020-08-24 | - | Kvartalsrapport 2021-Q1 |
2020-06-08 | - | Bokslutskommuniké 2020 |
2020-04-20 | - | Extra Bolagsstämma 2020 |
2020-03-02 | - | Kvartalsrapport 2020-Q3 |
2019-12-02 | - | Kvartalsrapport 2020-Q2 |
2019-09-30 | - | Årsstämma |
2019-09-25 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2019-09-02 | - | Kvartalsrapport 2020-Q1 |
2019-06-10 | - | Bokslutskommuniké 2019 |
2019-03-04 | - | Kvartalsrapport 2019-Q3 |
2018-12-17 | - | Kvartalsrapport 2019-Q2 |
2018-09-25 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
2018-09-24 | - | Årsstämma |
2018-09-24 | - | Kvartalsrapport 2019-Q1 |
2018-06-25 | - | Bokslutskommuniké 2018 |
2018-03-26 | - | Kvartalsrapport 2018-Q3 |
2017-12-18 | - | Kvartalsrapport 2018-Q2 |
2017-09-25 | - | Årsstämma |
2017-09-25 | - | Kvartalsrapport 2018-Q1 |
2017-06-30 | - | Bokslutskommuniké 2017 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Mölndal, Sweden, October 12, 2023 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the long-term follow-up of a patient who received a human-machine bionic hand prosthesis, utilizing the company's innovative implantable solution, has shown successful results. The groundbreaking system represents a future standard of advanced prosthetic solutions.
The patient case involves a Swedish woman who lost her right hand in a tragic accident over 20 years ago. Following reconstructive surgery, the woman received a below-elbow prosthesis based on Integrum's OPRA[TM] Implant System solution. The system was further refined advanced e-OPRA[TM] system with implanted electrodes, connected to a sophisticated AI system with the capability of relaying impulses, both to and from, a bionic hand equipped with heat and touch sensors.
The complete system has been used at home, allowing the carrier to perform simple and motorically complex everyday tasks. This is the first time clinicians and researchers have been able to achieve a long-term human-machine interface, connecting residual bones, nerves, and muscles into an electronic system to regain mobility. The study was published in the journal Science Robotics 2023-10-11 (https://www.science.org/toc/scirobotics/8/83).
The biological integration of titanium implants into bone tissue creates opportunities to advance amputee care further. By combining osseointegration with reconstructive surgery, implanted electrodes, and AI, we can restore human function in an unprecedented way. The below elbow amputation level has particular challenges, and the level of functionality achieved marks an important milestone for the field of advanced extremity reconstructions as a whole," says Rickard Brånemark, CEO of Integrum.
About the researchers and companies
The work was funded through the EU research program Horizon 2020 (DeTOP; GA #687905) and achieved through a joint-research project involving Integrum AB, researchers from the Center for Bionics and Pain Research (CBPR), the Bionics Institute in Melbourne, the Istituto Ortopedico Rizzoli, the Scuola Superiore Sant'Anna, the Massachusetts Institute of Technology, Lund University, the Swiss Center for Electronics and Microtechnology, INAIL Prosthetic Center, Universitá Campus Bio-Medico, and the companies TeamOlmed in Sweden, and Prensilia in Italy.
Rickard Brånemark, CEO. +46 (0) 70 846 10 61, E-mail: rickard.branemark@integrum.se
Certified Adviser
Erik Penser Bank is Certified Adviser.